Stem Cell Autograft Minimal Residual Disease Negativity Improves Outcomes after Autotransplant for Multiple Myeloma

被引：1

作者：

Nishimura, Noriko ^{[1
]}

Brown, Samantha ^{[2
]}

Devlin, Sean M. ^{[3
]}

Dahi, Parastoo B. ^{[4
,5
]}

Landau, Heather ^{[4
,6
]}

Lahoud, Oscar B. ^{[6
]}

Scordo, Michael ^{[4
,6
]}

Shah, Gunjan L. ^{[4
,7
]}

Hassoun, Hani ^{[8
]}

Hultcrantz, Malin ^{[8
]}

Korde, Neha ^{[8
]}

Lesokhin, Alexander M. ^{[5
,9
]}

Mailankody, Sham ^{[5
]}

Shah, Urvi A. ^{[8
]}

Tan, Carlyn ^{[8
]}

Usmani, Saad ^{[10
]}

Giralt, Sergio A. ^{[4
,11
]}

Chung, David J. ^{[4
,6
]}

Gupta, Gaurav ^{[12
]}

Maryamchik, Elena ^{[12
]}

Ntrivalas, Evangelos ^{[13
]}

Roshal, Mikhail ^{[14
]}

机构：

[1] Sloan Kettering Inst Canc Res, New York, NY USA

[2] Mem Sloan Kettering Canc Ctr, Dept Epidemiol Biostat, 1275 York Ave, New York, NY 10021 USA

[3] Mem Sloan Kettering Canc Ctr, Dept Epidemiol & Biostat, New York, NY 10021 USA

[4] Weill Cornell Med Coll, Dept Med, New York, NY USA

[5] Mem Sloan Kettering Canc Ctr, 1275 York Ave, New York, NY 10021 USA

[6] Mem Sloan Kettering Canc Ctr, Dept Med, Adult Bone Marrow Transplant Serv, 1275 York Ave, New York, NY 10021 USA

[7] Mem Sloan Kettering Canc Ctr, Dept Med, Adult Bone Marrow Transplant Serv, Cellular Therapy Serv, 1275 York Ave, New York, NY 10021 USA

[8] Mem Sloan Kettering Canc Ctr, Dept Med, Myeloma Serv, 1275 York Ave, New York, NY 10021 USA

[9] Weill Cornell Med Coll, New York, NY USA

[10] Levine Canc Inst, New York, NY USA

[11] Mem Sloan Kettering Canc Ctr, Dept Med, Adult Bone Marrow Transplantat Serv, 1275 York Ave, New York, NY 10021 USA

[12] Mem Sloan Kettering Canc Ctr, Dept Pathol & Lab Med, Transfus Med & Cell Therapy, 1275 York Ave, New York, NY 10021 USA

[13] Mem Sloan Kettering Canc Ctr, Dept Pathol & Lab Med, Cellular Immunol Serv, 1275 York Ave, New York, NY 10021 USA

[14] Mem Sloan Kettering Canc Ctr, Dept Pathol & Lab Med, Hematopathol Serv, 1275 York Ave, New York, NY 10021 USA

来源：

BLOOD | 2022年 / 140卷

关键词：

D O I：

10.1182/blood-2022-160271

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页数：3

共 50 条

[31] MONITORING OF MINIMAL RESIDUAL DISEASE (MRD) IN PATIENTS WITH MULTIPLE MYELOMA (MM) BEFORE AND AFTER AUTOLOGOUS STEM CELL TRANSPLANTATION (ASCT)
Galtseva, I.
Mendeleeva, L.
Pokrovskaya, O.
Kastrikina, I.
Urnova, E.
Kuzmina, L.
Parovichnikova, E.
Savchenko, V.
HAEMATOLOGICA, 2014, 99 : 647 - 647
[32] The relevance of minimal residual disease after autologous stem cell transplantation in patients with multiple myeloma (first results of a prospective study)
Solovev, M.
Mendeleeva, L.
Galtseva, I.
Pokrovskaya, O.
Firsova, M.
Nareyko, M.
Kuzmina, L.
Gemdzhian, E.
Savchenko, V.
BONE MARROW TRANSPLANTATION, 2016, 51 : S506 - S507
[33] Molecular monitoring of chimerism and minimal residual disease in multiple myeloma patients after non-myeloablative stem cell transplantation
Galimberti, S
Benedetti, E
Fazzi, R
Papineschi, F
Caracciolo, F
Orciuolo, E
Andreazzoli, F
Morabito, F
Cuzzola, M
Martino, M
Iacopino, P
Petrini, M
BONE MARROW TRANSPLANTATION, 2004, 33 : S112 - S112
[34] Multiple myeloma, immunotherapy and minimal residual disease
Kusenda, J.
Kovarikova, A.
NEOPLASMA, 2016, 63 (05) : 651 - 658
[35] Minimal residual disease monitoring in multiple myeloma
Davies, FE
Rawstron, RC
Owen, RG
Morgan, GJ
BEST PRACTICE & RESEARCH CLINICAL HAEMATOLOGY, 2002, 15 (01) : 197 - 222
[36] Standardisation of minimal residual disease in multiple myeloma
Innao, V.
Allegra, A.
Russo, S.
Gerace, D.
Vaddinelli, D.
Alonci, A.
Allegra, A. G.
Musolino, C.
EUROPEAN JOURNAL OF CANCER CARE, 2017, 26 (06)
[37] Sustained minimal residual disease negativity in newly diagnosed multiple myeloma and the impact of daratumumab in MAIA and ALCYONE
San-Miguel, Jesus
Avet-Loiseau, Herve
Paiva, Bruno
Kumar, Shaji
Dimopoulos, Meletios A.
Facon, Thierry
Mateos, Maria-Victoria
Touzeau, Cyrille
Jakubowiak, Andrzej
Usmani, Saad Z.
Cook, Gordon
Cavo, Michele
Quach, Hang
Ukropec, Jon
Ramaswami, Priya
Pei, Huiling
Qi, Mia
Sun, Steven
Wang, Jianping
Krevvata, Maria
DeAngelis, Nikki
Heuck, Christoph
Van Rampelbergh, Rian
Kudva, Anupa
Kobos, Rachel
Qi, Ming
Bahlis, Nizar J.
BLOOD, 2022, 139 (04) : 492 - 501
[38] MINIMAL RESIDUAL DISEASE NEGATIVITY AS A MEASURE OF RESPONSE TO CILTACABTAGENE AUTOLEUCEL IN PATIENTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA
Aronson, Elizabeth
Madduri, Deepu
Suarez, Jacklyn
Florendo, Erika
Pacaud, Lida
Steinbach, Mary
ONCOLOGY NURSING FORUM, 2023, 50 (02)
[39] Impact of Minimal Residual Disease Status on Multiple Myeloma Outcomes: A Systematic Review
Amin, Muhammad Kashif
Irfan, Sohaib
Khan, Muhammad Atif
Zahra, Fatima Tuz
Mohammad, Turab
Mushtaq, Muhammad Umair
Shahzad, Moazzam
BLOOD, 2024, 144 : 6952 - 6952
[40] Multiparameter Flow Cytometry For Detection Of Minimal Residual Disease In Multiple Myeloma After T-Cell Depleted Allogeneic Stem Cell Transplant
Kosuri, Satyajit
Smith, Katherine M.
Kuk, Deborah
Devlin, Sean M.
Maslak, Peter G.
Giralt, Sergio
Koehne, Guenther
BLOOD, 2013, 122 (21) : 4647 - 4649

← 1 2 3 4 5 →